Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Anthony S. Stein, MD, Roland B. Walter, MD PhD MS, Harry P Erba, MD PhD, Amir T. Fathi, MD, Anjali S. Advani, MD, Jeffrey E Lancet, MD, Farhad Ravandi, MD, Tibor J. Kovacsovics, MD, Daniel J. DeAngelo, MD PhD, Dale Bixby, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Eytan M Stein

Blood (2015) 126 (23): 324.

https://doi.org/10.1182/blood.V126.23.324.324

Published: 2015

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Amir T. Fathi, MD, Harry P Erba, MD PhD, Jeffrey E Lancet, MD, Eytan M Stein, Roland B. Walter, MD PhD MS, Daniel J. DeAngelo, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Anjali S. Advani, MD, Dale Bixby, MD PhD, Tibor J. Kovacsovics, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, Anthony S. Stein, MD

Blood (2015) 126 (23): 454.

https://doi.org/10.1182/blood.V126.23.454.454

Published: 2015

Journal Articles

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Shiven B. Patel, MD, Clinton C. Mason, PhD, Martha Glenn, MD, Christian N. Paxton, PhD, Sarah T. South, PhD, Melissa H. Cessna, MD, Julie D. Asch, MD, Erin F. Cobain, MD, Dale Bixby, MD PhD, Lauren B. Smith, MD, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Joshua D. Schiffman, MD, Rodney R. Miles, MD PhD

Blood (2015) 126 (23): 1427.

https://doi.org/10.1182/blood.V126.23.1427.1427

Published: 2015

Journal Articles

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Nagendra Mogasala, Sumana Devata, MD, Anthony Perissinotti, PharmD, Dale Bixby, MD PhD

Blood (2014) 124 (21): 2297.

https://doi.org/10.1182/blood.V124.21.2297.2297

Published: 2014

Journal Articles

Recurrent STAT6 Mutations In Follicular Lymphoma

Sami Malek, MD, Mark S. Kaminski, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, PA-C, Kathryn Jacobi, NP, Kamlai Saiya-Cork, Dale Bixby, MD, PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mehmet Yildiz, MD

Blood (2013) 122 (21): 503.

https://doi.org/10.1182/blood.V122.21.503.503

Published: 2013

Journal Articles

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Sami Malek, MD, Yifeng Li, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, Kathryn Jacobi, Kamlai saiya-Cork, Dale Bixby, MD PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 147.

https://doi.org/10.1182/blood.V120.21.147.147

Published: 2012

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

Journal Articles

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

Daryl Sonnichsen, David Dorer, Jorge E. Cortes, Moshe Talpaz, MD, Michael W. Deininger, MD, PhD, Neil Shah, MD, PhD, Hagop M. Kantarjian, Dale Bixby, MD PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Jeffrey Litwin, MD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD

Blood (2011) 118 (21): 4441.

https://doi.org/10.1182/blood.V118.21.4441.4441

Published: 2011

Journal Articles

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Jorge E. Cortes, Moshe Talpaz, MD, Hagop M Kantarjian, Hedy Smith, MD, PhD, Dale Bixby, MD, PhD, Usha Rafferty, MS, Mark S. Berger, MD, Scott C. Wise, MS, Tom J. Rutkoski, Ph.D, Bryan Smith, Ph.D, Richard A. Van Etten, MD PhD

Blood (2011) 118 (21): 601.

https://doi.org/10.1182/blood.V118.21.601.601

Published: 2011

Journal Articles

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Jorge E. Cortes, Hagop M. Kantarjian, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, Simin Hu, PhD, Tim Clackson, PhD, Victor M. Rivera, PhD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD, Brian J. Druker, Michael W. Deininger, Moshe Talpaz, MD

Blood (2011) 118 (21): 602.

https://doi.org/10.1182/blood.V118.21.602.602

Published: 2011

NARROW

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Recurrent STAT6 Mutations In Follicular Lymphoma

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only